Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-effect of esketamine to prevent postpartum depression after cesarean section
ChiCTR2400085315Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of esketamine in postpartum depression (PPD) and postoperative pain (5 arms), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoints: Incidence of postpartum depression at 6 weeks after operation and Postoperative pain VAS score at rest and during movement on days 1, 2, and 3. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
postpartum depression (PPD)postoperative pain
Beyond the preview
Go deeper on ChiCTR2400085315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085315.